Top

BMC Cancer

Published in:

Open Access 01-12-2023 | Breast Cancer | Research

Clinical implications and immune features of CENPN in breast cancer

Authors: Zhengwei Gui, Yao Tian, Tianyao Yu, Shiyang Liu, Chenguang Liu, Lin Zhang

Published in: BMC Cancer | Issue 1/2023

Abstract

Background

A number of human diseases have been associated with Centromere protein N (CENPN), but its role in breast cancer is unclear.

Methods

A pan-cancer database of Genotype Tissue Expression (GTEx) and the Cancer Genome Atlas (TCGA) were used to examine the expression of CENPN. Using TCGA clinical survival data and breast cancer specimens from our center for validation, the relationship between CENPN expression, breast cancer prognosis, and clinicopathological characteristics of patients was examined. Bioinformatics was utilized to conduct an enrichment study of CENPN. Additionally, the potential of CENPN as a predictive biomarker for immunotherapy success was confirmed by analyzing the co-expression of CENPN with immune-checkpoint related genes, reviewing the TCGA database, and evaluating the correlation between CENPN expression and immune cell infiltration. Using the CCK8 test and colony formation assay, CENPN was evaluated for its ability to inhibit breast cancer cell proliferation. Transwell assays and scratch tests were used to assess the impact of CENPN on breast cancer cell migration.

Results

CENPN is found in a wide range of tumors, including breast cancer. Additional investigation revealed that CENPN was co-expressed with the majority of immune checkpoint-related genes, had the potential to serve as a predictive biomarker for immunotherapy effectiveness, and that high CENPN expression was linked to high Tregs and low CD8 + T cells and NK cells. Breast cancer cells' malignant characteristics, such as migration and cell proliferation, were inhibited by CENPN knockdown.

Conclusions

According to our findings, CENPN may be an oncogene in breast cancer, as well as a new therapeutic target for immune checkpoint inhibitors.

Available only for authorised users

Chen H, et al. Centromere protein F is identified as a novel therapeutic target by genomics profile and contributing to the progression of pancreatic cancer. Genomics. 2021;113:1087–95. https://doi.org/10.1016/j.ygeno.2020.10.039.CrossRefPubMed

Mi YJ, et al. Prognostic relevance and therapeutic implications of centromere protein F expression in patients with esophageal squamous cell carcinoma. Dis Esophagus. 2013;26:636–43. https://doi.org/10.1111/dote.12002.CrossRefPubMed

O’Brien SL, et al. CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer. Int J Cancer. 2007;120:1434–43. https://doi.org/10.1002/ijc.22413.CrossRefPubMedPubMedCentral

Weng MY, Li L, Hong SJ, Feng SY. Clinical Significance of CENP-H Expression in Uterine Cervical Cancer. Cancer Biol Med. 2012;9:192–6. https://doi.org/10.7497/j.issn.2095-3941.2012.03.007.CrossRefPubMedPubMedCentral

Liao WT, et al. Overexpression of centromere protein H is significantly associated with breast cancer progression and overall patient survival. Chin J Cancer. 2011;30:627–37. https://doi.org/10.5732/cjc.010.10599.CrossRefPubMedPubMedCentral

He WL, et al. Combined evaluation of centromere protein H and Ki-67 as prognostic biomarker for patients with gastric carcinoma. Eur J Surg Oncol. 2013;39:141–9. https://doi.org/10.1016/j.ejso.2012.08.023.CrossRefPubMed

Allu P, et al. Structure of the Human Core Centromeric Nucleosome Complex. Curr Biol. 2019;29:2625-2639 e2625. https://doi.org/10.1016/j.cub.2019.06.062.CrossRefPubMedPubMedCentral

Tian T, et al. Molecular basis for CENP-N recognition of CENP-A nucleosome on the human kinetochore. Cell Res. 2018;28:374–8. https://doi.org/10.1038/cr.2018.13.CrossRefPubMedPubMedCentral

Pentakota, S. et al. Decoding the centromeric nucleosome through CENP-N. Elife. 2017; 6: https://doi.org/10.7554/eLife.33442.

10.

McKinley KL, et al. The CENP-L-N Complex Forms a Critical Node in an Integrated Meshwork of Interactions at the Centromere-Kinetochore Interface. Mol Cell. 2015;60:886–98. https://doi.org/10.1016/j.molcel.2015.10.027.CrossRefPubMedPubMedCentral

11.

Zheng Y, et al. Centromere protein N promotes lung adenocarcinoma progression by activating PI3K/AKT signaling pathway. Genes Genomics. 2022;44:1039–49. https://doi.org/10.1007/s13258-021-01215-8.CrossRefPubMed

12.

Qi CL, et al. The IRF2/CENP-N/AKT signaling axis promotes proliferation, cell cycling and apoptosis resistance in nasopharyngeal carcinoma cells by increasing aerobic glycolysis. J Exp Clin Cancer Res. 2021;40:390. https://doi.org/10.1186/s13046-021-02191-3.CrossRefPubMedPubMedCentral

13.

Liu J, et al. An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell. 2018;173:400-416 e411. https://doi.org/10.1016/j.cell.2018.02.052.CrossRefPubMedPubMedCentral

14.

Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7. https://doi.org/10.1186/1471-2105-14-7.CrossRefPubMedPubMedCentral

15.

Bindea G, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39:782–95. https://doi.org/10.1016/j.immuni.2013.10.003.CrossRefPubMed

16.

Danilova L, et al. Programmed Cell Death Ligand-1 (PD-L1) and CD8 Expression Profiling Identify an Immunologic Subtype of Pancreatic Ductal Adenocarcinomas with Favorable Survival. Cancer Immunol Res. 2019;7:886–95. https://doi.org/10.1158/2326-6066.CIR-18-0822.CrossRefPubMedPubMedCentral

17.

Jiang P, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24:1550–8. https://doi.org/10.1038/s41591-018-0136-1.CrossRefPubMedPubMedCentral

18.

Wang Q, et al. Analysis of immune-related signatures of lung adenocarcinoma identified two distinct subtypes: implications for immune checkpoint blockade therapy. Aging (Albany NY). 2020;12:3312–39. https://doi.org/10.18632/aging.102814.CrossRefPubMed

19.

Navarro AP, Cheeseman IM. Kinetochore assembly throughout the cell cycle. Semin Cell Dev Biol. 2021;117:62–74. https://doi.org/10.1016/j.semcdb.2021.03.008.CrossRefPubMedPubMedCentral

20.

Navarro AP, Cheeseman IM. Chromosome Segregation: Evolving a Plastic Chromosome-Microtubule Interface. Curr Biol. 2020;30:R174–7. https://doi.org/10.1016/j.cub.2019.12.058.CrossRefPubMed

21.

Chittori S, et al. Structural mechanisms of centromeric nucleosome recognition by the kinetochore protein CENP-N. Science. 2018;359:339–43. https://doi.org/10.1126/science.aar2781.CrossRefPubMed

22.

Khong HT, Restifo NP. Natural selection of tumor variants in the generation of “tumor escape” phenotypes. Nat Immunol. 2002;3:999–1005. https://doi.org/10.1038/ni1102-999.CrossRefPubMedPubMedCentral

23.

Locy H, et al. Immunomodulation of the Tumor Microenvironment: Turn Foe Into Friend. Front Immunol. 2018;9:2909. https://doi.org/10.3389/fimmu.2018.02909.CrossRefPubMedPubMedCentral

24.

Wherry EJ, Ahmed R. Memory CD8 T-cell differentiation during viral infection. J Virol. 2004;78:5535–45. https://doi.org/10.1128/JVI.78.11.5535-5545.2004.CrossRefPubMedPubMedCentral

25.

Goswami KK, Bose A, Baral R. Macrophages in tumor: An inflammatory perspective. Clin Immunol. 2021;232:108875. https://doi.org/10.1016/j.clim.2021.108875.CrossRefPubMed

26.

Liu C, et al. Treg Cells Promote the SREBP1-Dependent Metabolic Fitness of Tumor-Promoting Macrophages via Repression of CD8(+) T Cell-Derived Interferon-gamma. Immunity. 2019;51:381-397 e386. https://doi.org/10.1016/j.immuni.2019.06.017.CrossRefPubMedPubMedCentral

27.

Anderson NR, Minutolo NG, Gill S, Klichinsky M. Macrophage-based approaches for cancer immunotherapy. Cancer Res. 2021;81:1201–8. https://doi.org/10.1158/0008-5472.CAN-20-2990.CrossRefPubMed

28.

Rizzo A, et al. KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer. Future Oncol. 2022;18:2301–9. https://doi.org/10.2217/fon-2021-1647.CrossRefPubMed

29.

Deutschmann C, et al. Atezolizumab plus nab-paclitaxel for unresectable, locally advanced or metastatic breast cancer: real-world results from a single academic center in Austria. BMC Cancer. 2022;22:1099. https://doi.org/10.1186/s12885-022-10168-4.CrossRefPubMedPubMedCentral

30.

Schmid P, et al. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study. Ann Oncol. 2020;31:569–81. https://doi.org/10.1016/j.annonc.2020.01.072.CrossRefPubMed

Title: Clinical implications and immune features of CENPN in breast cancer
Authors: Zhengwei Gui
Yao Tian
Tianyao Yu
Shiyang Liu
Chenguang Liu
Lin Zhang
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Breast Cancer
Breast Cancer
Published in: BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-023-11376-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2023

Efficacy and safety of mirogabalin for chemotherapy-induced peripheral neuropathy: a prospective single-arm trial (MiroCIP study)

Using RegGAN to generate synthetic CT images from CBCT images acquired with different linear accelerators

Developing a predictive nomogram for colposcopists: a retrospective, multicenter study of cervical precancer identification in China

Prognostic impact of severe neutropenia in colorectal cancer patients treated with TAS-102 and bevacizumab, addressing immortal-time bias

Preparation of chitosan nanoparticle containing recombinant CD44v antigen and evaluation of its immunization capacity against breast cancer in BALB/c mice

Analysis of patients with colorectal cancer shows a specific increase in serum anti-ING1 autoantibody levels

Keynote webinar | Spotlight on antibody–drug conjugates in cancer